/ELIC.ST
ELIC.ST Stock - Elicera Therapeutics AB (publ)
Healthcare|BiotechnologySTO
$5.59+3.52%
+$0.19 (+3.52%) • Dec 23
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.46
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $6.15
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ELIC.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.53 – $5.65
TARGET (TP)$6.43
STOP LOSS$5.14
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.42
52W High$8.43
52W Low$1.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.13M | $11.23M | $1.28M | $587 | N/A |
| Gross Profit | $7.13M | $11.22M | $1.28M | $-11,189 | $-11,776 |
| Gross Margin | 100.0% | 99.9% | 100.0% | -1906.1% | N/A |
| Operating Income | $-16,884,000 | $-28,326,340 | $-19,363,000 | $-13,119,368 | $-2,828,545 |
| Net Income | $-16,110,000 | $-16,398,000 | $-19,515,000 | $-13,120,443 | $-2,823,127 |
| Net Margin | -226.0% | -146.0% | -1524.6% | -2235169.2% | N/A |
| EPS | $-0.51 | $-0.83 | $-0.98 | $-0.82 | $-0.15 |
Company Overview
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ELIC.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.06
Q2 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | — | — | — |
Q2 2025 | Jun 30, 2025 | — | $-0.06 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.22 | — | — |
Q1 2025 | Feb 3, 2025 | — | $-0.07 | — | — |
Q4 2024 | Nov 28, 2024 | — | $-0.05 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.16 | — | — |
Q2 2024 | May 27, 2024 | — | $-0.25 | — | — |
Q1 2024 | Feb 13, 2024 | — | $-0.24 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.26 | — | — |
Q3 2023 | Aug 29, 2023 | — | $-0.22 | — | — |
Q2 2023 | May 16, 2023 | — | $-0.11 | — | — |
Q1 2023 | Feb 17, 2023 | — | $-0.19 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.30 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.16 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.20 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.11 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.34 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.15 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.13 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.14 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ELIC.ST
What is ELIC.ST's current stock price?
Elicera Therapeutics AB (publ) (ELIC.ST) is currently trading at $5.59 per share. The stock has moved +3.52% today.
What is the analyst price target for ELIC.ST?
No analyst price targets are currently available for this stock.
What sector is Elicera Therapeutics AB (publ) in?
Elicera Therapeutics AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is ELIC.ST's market cap?
Elicera Therapeutics AB (publ) has a market capitalization of $0.27 billion, making it a small-cap company.
Does ELIC.ST pay dividends?
No, Elicera Therapeutics AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACARIX.ST
Acarix AB (publ)
$0.28
Mkt Cap: $0.3B
ACE.ST
Ascelia Pharma AB (publ)
$3.17
Mkt Cap: $0.4B
BIOWKS.ST
Bio-Works Technologies AB (publ)
$2.25
Mkt Cap: $0.2B
IMMU.ST
Mendus AB (publ)
$5.30
Mkt Cap: $0.3B
INIT.ST
Initiator Pharma A/S
$2.93
Mkt Cap: $0.2B
IVACC.ST
Intervacc AB (publ)
$0.92
Mkt Cap: $0.3B
KDEV.ST
Karolinska Development AB (publ)
$0.43
Mkt Cap: $0.1B
MAGLE.ST
Magle Chemoswed Holding AB (publ)
$17.20
Mkt Cap: $0.4B
NANEXA.ST
Nanexa AB (publ)
$4.21
Mkt Cap: $0.7B
XINT.ST
Xintela AB (publ)
$0.27
Mkt Cap: $0.2B
Explore stocks similar to ELIC.ST for comparison